A science-based enterprise, specializing in molecular diagnostics for transplantation and personalized health care!
Headquartered in the Netherlands.
GenDx develops and markets a comprehensive line of In Vitro Diagnostic (IVD) tests and services, analysis software and education. The company is a pioneer in the area of Sequencing-Based Typing (SBT) for transplantation.
GenDx was founded in March 2005 by Erik Rozemuller, Wietse Mulder and Oscar Schoots (representing UMC participaties B.V.).
GenDx has long-standing strategic alliances with renowned business partners, providing access to a large global customer base. GenDx is a privately owned, independent company with experienced management and a close-knit team of dedicated employees headquartered in the Netherlands.
The company has over 50 employees allowing GenDx to be able to support HLA typing laboratories with the newest technologies and optimized workflows for HLA typing. GenDx offers a unique approach for Sanger-based strategies, and Next-Generation Sequencing approaches.
